TEE
ABEO icon

Tibra Equities Europe’s Abeona Therapeutics ABEO Stock Holding History

Tibra Equities Europe’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,988
Closed -$312K – 40
2021
Q2 		$312K Buy
+7,988
New +$326K 0.1% 163

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Tibra Equities Europe's ABEO Position: Q3 2021 in Review

Tibra Equities Europe sold out of Abeona Therapeutics (ABEO) in Q3 2021, closing a stake of 7,988 shares — an estimated $312K sold.

Tibra Equities Europe first reported a position in ABEO in Q2 2021 and held it in 1 quarter. The position peaked at $312K in Q2 2021. 58 funds tracked by Wall St. Rank hold ABEO as of Q3 2021.

  • Tibra Equities Europe reported no remaining Abeona Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 7,988 Abeona Therapeutics shares in Q3 2021, an estimated $312K.
  • Tibra Equities Europe first reported a position in Abeona Therapeutics in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Abeona Therapeutics position peaked at $312K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.